{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-227920","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-05-18T12:00:16+00:00","discovered_at":"2026-05-18T12:05:00.408748+00:00","generated_at":"2026-05-18T12:09:22.612329+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kyverna appoints Greg Martini as CFO; Marc Grasso transitions to strategic advisor","bullets":["Greg Martini named CFO effective May 18, 2026; previously CFO of Ironwood Pharmaceuticals.","Marc Grasso steps down as CFO, stays as strategic advisor through Aug 1, 2026 for transition.","Compensation: $525K salary, 40% bonus target, $300K sign-on bonus, 325K stock option (4-year vest).","Company advancing miv-cel (KYV-101) toward potential first approval in stiff person syndrome.","Option grant of 325K shares as inducement under Nasdaq Rule 5635(c)(4); exercise price May 18 close."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-227920","json":"https://secwatch.observer/filing/0001193125-26-227920.json","markdown":"https://secwatch.observer/filing/0001193125-26-227920.md","text":"https://secwatch.observer/filing/0001193125-26-227920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526227920/0001193125-26-227920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526227920/kytx-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T12:09:22.612329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ecfa67f52","claim":"Gregory Martini was appointed as Chief Financial Officer at Kyverna Therapeutics, Inc..","evidence_excerpt":"On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526227920/0001193125-26-227920-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}